In brief
- A pilot trial at Yale University compared one and two doses of psilocybin (10 mg) against diphenhydramine as an active placebo in 18 people with migraines.
- 80% of those who received psilocybin responded to the treatment, compared to 17% in the placebo group, though the difference did not reach statistical significance due to the small sample size.
- No serious adverse effects were reported; the main challenge of the study was achieving complete blinding against the placebo.
A new clinical trial from Yale University has explored whether administering psilocybin in one or two doses can prevent migraine episodes, comparing it for the first time to an active placebo capable of mimicking some of its subjective effects. The results, published in the journal Headache: The Journal of Head and Face Pain, point to a notable clinical response, although the authors themselves emphasize that this is an exploratory, small-scale study.
A placebo designed to stay hidden
The team led by Emmanuelle Schindler, who researches psychedelics for headaches at the Yale School of Medicine, recruited 18 adults with migraines who experienced at least two days of pain per week. Participants underwent two sessions separated by seven days, divided into three groups: active placebo (diphenhydramine) in both; diphenhydramine followed by a 10 mg dose of psilocybin; or 10 mg of psilocybin in both sessions, replicating the “pulse” dosing already tested for cluster headaches. Using an active placebo aimed to resolve a classic problem in psychedelic studies: if the participant notices they have received the substance, it is difficult to distinguish the pharmacological effect from expectation.
Greater clinical response, without firm statistical significance
In the two weeks following treatment, migraine days per week dropped by 0.7 in the placebo group, 2.0 with one dose of psilocybin, and 1.7 with two doses; the difference between groups was not statistically significant (p = 0.102), which is expected with only 18 people across three arms. The clinical response rate was notable: 80% of those who received psilocybin responded to the treatment, compared to 17% with the active placebo (p = 0.087, bordering on conventional significance), with large effect sizes. At eight weeks, the improvement had leveled off across all groups to around 50%, pointing to a relevant medium-term placebo response component. There were no serious adverse effects, and the authors admit that blinding was incomplete: diphenhydramine does not fully mimic the subjective experience of psilocybin.
What it implies
The trial adds to the line of research the same Yale group has pursued since 2020 regarding psilocybin for migraine and cluster headaches, reinforcing a recurring idea: low doses, well below those used in mental health, could have a preventive effect on recurrent headaches. It is wise to be cautious: the sample is minimal, the design is exploratory, and the team admits that incomplete blinding complicates the interpretation of such favorable results. The authors call for larger samples and more convincing active placebos to confirm whether the improvement is attributable to psilocybin or, in part, to expectation. Even so, the absence of serious adverse effects and the magnitude of the clinical response justify continuing to explore this path for chronic migraine, where current preventive options leave many people without sufficient relief.
Source
- Schindler EAD, Gottschalk CH, Pittman BP, D’Souza DC. Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial. Headache: The Journal of Head and Face Pain, published online December 29, 2025 (April 2026 issue).
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
